Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

Interdisciplinary multimodality management of stage III nonsmall cell lung cancer.

Huber RM, De Ruysscher D, Hoffmann H, Reu S, Tufman A.

Eur Respir Rev. 2019 Jul 8;28(152). pii: 190024. doi: 10.1183/16000617.0024-2019. Print 2019 Jun 30. Review.

2.

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Reck M, Kerr KM, Grohé C, Manegold C, Pavlakis N, Paz-Ares L, Huber RM, Popat S, Thatcher N, Park K, Hilberg F, Barrueco J, Kaiser R.

Future Oncol. 2019 Apr;15(12):1363-1383. doi: 10.2217/fon-2018-0948. Epub 2019 Feb 13. Review.

3.

Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.

Rich A, Baldwin D, Alfageme I, Beckett P, Berghmans T, Brincat S, Burghuber O, Corlateanu A, Cufer T, Damhuis R, Danila E, Domagala-Kulawik J, Elia S, Gaga M, Goksel T, Grigoriu B, Hillerdal G, Huber RM, Jakobsen E, Jonsson S, Jovanovic D, Kavcova E, Konsoulova A, Laisaar T, Makitaro R, Mehic B, Milroy R, Moldvay J, Morgan R, Nanushi M, Paesmans M, Putora PM, Samarzija M, Scherpereel A, Schlesser M, Sculier JP, Skrickova J, Sotto-Mayor R, Strand TE, Van Schil P, Blum TG.

BMC Cancer. 2018 Nov 20;18(1):1144. doi: 10.1186/s12885-018-5009-y.

4.

Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.

Kauffmann-Guerrero D, Kahnert K, Kumbrink J, Syunyaeva Z, Tufman A, Huber RM.

Clin Lung Cancer. 2019 Jan;20(1):59-62. doi: 10.1016/j.cllc.2018.09.009. Epub 2018 Sep 21. No abstract available.

PMID:
30341016
5.

Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy.

Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, Goldscheider I, Kauffmann-Guerrero D, Huber RM, Dechant C, Berking C, Schulze-Koops H, Skapenko A.

RMD Open. 2018 Aug 17;4(2):e000714. doi: 10.1136/rmdopen-2018-000714. eCollection 2018.

6.

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.

Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M, Kollmeier J, Sadjadian P, Fröhling KP, Huber RM, Wolf M; IMPULSE study team.

Ann Oncol. 2018 Oct 1;29(10):2076-2084. doi: 10.1093/annonc/mdy326.

7.

Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC.

Kauffmann-Guerrero D, Kahnert K, Syunyaeva Z, Tufman A, Huber RM.

Oncol Res Treat. 2018;41(9):506-512. doi: 10.1159/000488688. Epub 2018 Aug 8.

8.

Less radiation, same quality: contrast-enhanced multi-detector computed tomography investigation of thoracic lymph nodes with one milli-sievert.

Mueller-Lisse UG, Marwitz L, Tufman A, Huber RM, Zimmermann HA, Walterham A, Wirth S, Paolini M.

Radiol Med. 2018 Nov;123(11):818-826. doi: 10.1007/s11547-018-0915-2. Epub 2018 Jun 30.

PMID:
29961228
9.

How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.

Roengvoraphoj O, Eze C, Wijaya C, Dantes M, Taugner J, Tufman A, Huber RM, Bartenstein P, Belka C, Manapov F.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2103-2109. doi: 10.1007/s00259-018-4063-7. Epub 2018 Jun 6.

PMID:
29876620
10.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

11.

Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography.

Götschke J, Mertsch P, Kneidinger N, Kauffmann-Guerrero D, Behr J, Huber RM, Reichenberger F, Milger K.

Can Respir J. 2018 Apr 1;2018:9649716. doi: 10.1155/2018/9649716. eCollection 2018.

12.

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN.

J Clin Oncol. 2018 Sep 10;36(26):2693-2701. doi: 10.1200/JCO.2017.77.5841. Epub 2018 May 16.

PMID:
29768119
13.

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.

14.

Dermal Filler Injections Mimic Tumor Activity during Immune Checkpoint Inhibition.

Syunyaeva Z, Kahnert K, Kauffmann-Guerrero D, Huber RM, Tufman A.

Respiration. 2018;95(5):362-363. doi: 10.1159/000487601. Epub 2018 Apr 5. No abstract available.

15.

Correction to: Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.

Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, Tufman A, Huber RM, Belka C, Manapov F.

Strahlenther Onkol. 2018 Apr;194(4):363-364. doi: 10.1007/s00066-018-1290-6.

PMID:
29541791
16.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

17.

Heterogeneous pattern of differences in respiratory parameters between elderly with either good or poor FEV1.

Karrasch S, Behr J, Huber RM, Nowak D, Peters A, Peters S, Holle R, Jörres RA, Schulz H; KORA Study Group.

BMC Pulm Med. 2018 Feb 6;18(1):27. doi: 10.1186/s12890-018-0582-z.

18.

SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.

Moncayo G, Grzmil M, Smirnova T, Zmarz P, Huber RM, Hynx D, Kohler H, Wang Y, Hotz HR, Hynes NE, Keller G, Frank S, Merlo A, Hemmings BA.

Neuro Oncol. 2018 Apr 9;20(5):621-631. doi: 10.1093/neuonc/noy008.

19.

NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.

Kauffmann-Guerrero D, Huber RM, Reu S, Tufman A, Mertsch P, Syunyaeva Z, Jung A, Kahnert K.

Respiration. 2018;95(3):169-176. doi: 10.1159/000484175. Epub 2017 Nov 30.

20.

Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer.

Tufman A, Kahnert K, Duell T, Kauffmann-Guerrero D, Milger K, Schneider C, Stump J, Syunyaeva Z, Huber RM, Reu S.

Onco Targets Ther. 2017 Oct 25;10:5179-5186. doi: 10.2147/OTT.S140472. eCollection 2017.

21.

Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.

Roengvoraphoj O, Wijaya C, Eze C, Li M, Dantes M, Taugner J, Tufman A, Huber RM, Belka C, Manapov F.

Strahlenther Onkol. 2018 Feb;194(2):107-115. doi: 10.1007/s00066-017-1229-3. Epub 2017 Nov 7. Erratum in: Strahlenther Onkol. 2018 Mar 14;:.

PMID:
29116336
22.

Perception of climate change in patients with chronic lung disease.

Götschke J, Mertsch P, Bischof M, Kneidinger N, Matthes S, Renner ED, Schultz K, Traidl-Hoffmann C, Duchna HW, Behr J, Schmude J, Huber RM, Milger K.

PLoS One. 2017 Oct 18;12(10):e0186632. doi: 10.1371/journal.pone.0186632. eCollection 2017.

23.

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.

J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27. Review.

24.

Black and Blue.

Kauffmann-Guerrero D, Kahnert K, Pratschke S, Angstwurm M, Tufman A, Huber RM.

Respiration. 2017;94(5):465-466. doi: 10.1159/000479703. Epub 2017 Sep 7. No abstract available.

25.

Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort.

Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, Watz H, Alter P, Fähndrich S, Bals R, Holle R, Karrasch S, Söhler S, Wacker M, Ficker JH, Parhofer KG, Vogelmeier C, Jörres RA; COSYCONET consortium.

PLoS One. 2017 May 15;12(5):e0177501. doi: 10.1371/journal.pone.0177501. eCollection 2017.

26.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR.

J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5.

PMID:
28475456
27.

Assessment of lung function in a large cohort of patients with acromegaly.

Störmann S, Gutt B, Roemmler-Zehrer J, Bidlingmaier M, Huber RM, Schopohl J, Angstwurm MW.

Eur J Endocrinol. 2017 Jul;177(1):15-23. doi: 10.1530/EJE-16-1080. Epub 2017 Apr 21.

PMID:
28432267
28.

Cancer vaccination causes prolonged FDG accumulation in subcutaneous tissue.

Kahnert K, Kauffmann-Guerrero D, Tufman A, Borgmeier A, Huber RM, Berger F.

Nuklearmedizin. 2017 Apr 21. doi: 10.3413/Nukmed-0868-16-12. [Epub ahead of print] No abstract available.

PMID:
28429815
29.

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial.

Guetz S, Tufman A, von Pawel J, Rittmeyer A, Borgmeier A, Ferré P, Edlich B, Huber RM.

Onco Targets Ther. 2017 Feb 21;10:1081-1089. doi: 10.2147/OTT.S122106. eCollection 2017.

30.

Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer.

Tufman A, Kahnert K, Kauffmann-Guerrero D, Manapov F, Milger K, Müller-Lisse U, Winter H, Huber RM, Schneider C.

Strahlenther Onkol. 2017 May;193(5):392-401. doi: 10.1007/s00066-017-1118-9. Epub 2017 Feb 28.

PMID:
28246699
31.

[Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study].

Heigener DF, Hoeffken G, Wuerflein D, Feurer M, Rittmeyer A, Huber RM, Pietsch M, Ring A, Deppermann KM.

Dtsch Med Wochenschr. 2017 Feb;142(4):e21-e27. doi: 10.1055/s-0042-121785. Epub 2017 Feb 24. German.

PMID:
28235221
32.

Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology.

Gamarra F, Noël JL, Brunelli A, Dingemans AC, Felip E, Gaga M, Grigoriu BD, Hardavella G, Huber RM, Janes S, Massard G, Putora PM, Sculier JP, Schnabel PA, Ramella S, Van Raemdonck D, Meert AP.

Breathe (Sheff). 2016 Sep;12(3):249-255. doi: 10.1183/20734735.009116. Review.

33.

Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort.

Kahnert K, Lucke T, Biertz F, Lechner A, Watz H, Alter P, Bals R, Behr J, Holle R, Huber RM, Karrasch S, Stubbe B, Wacker M, Söhler S, Wouters EF, Vogelmeier C, Jörres RA; COSYCONET study group.

Respir Res. 2017 Jan 13;18(1):14. doi: 10.1186/s12931-016-0499-0.

35.

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.

Brückl W, Tufman A, Huber RM.

Expert Rev Anticancer Ther. 2017 Feb;17(2):143-155. doi: 10.1080/14737140.2017.1266265. Epub 2016 Dec 12. Review.

PMID:
27898252
36.

Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies - A Novel Stepwise Approach by Evaluation of Medication.

Lucke T, Herrera R, Wacker M, Holle R, Biertz F, Nowak D, Huber RM, Söhler S, Vogelmeier C, Ficker JH, Mückter H, Jörres RA; COSYCONET-Consortium.

PLoS One. 2016 Oct 28;11(10):e0163408. doi: 10.1371/journal.pone.0163408. eCollection 2016.

37.

Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.

Rosell R, Neninger E, Nicolson M, Huber RM, Thongprasert S, Parikh PM, D'Hondt E.

J Thorac Oncol. 2016 Nov;11(11):1954-1961. doi: 10.1016/j.jtho.2016.08.132. Epub 2016 Aug 24.

38.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

39.

From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel.

Su C, Meyer M, Pirker R, Voigt W, Shi J, Pilz L, Huber RM, Wu Y, Wang J, He Y, Wang X, Zhang J, Zhi X, Shi M, Zhu B, Schoenberg SS, Henzler T, Manegold C, Zhou C, Roessner ED.

Transl Lung Cancer Res. 2016 Aug;5(4):377-88. doi: 10.21037/tlcr.2016.07.09. Review.

40.

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.

Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Brunsvig PF, Scagliotti GV, Scolaro T.

Lung Cancer. 2016 Oct;100:30-37. doi: 10.1016/j.lungcan.2016.07.026. Epub 2016 Jul 27.

41.

A persistent pneumothorax? 5-year follow-up after diagnosis of Swyer-James-MacLeod syndrome.

Tufman A, Winter H, Kahnert K, Reu S, Müller-Lisse U, Huber RM.

Breathe (Sheff). 2016 Jun;12(2):e55-E58. doi: 10.1183/20734735.000316.

42.

SCLC-State of the Art and What Does the Future Have in Store?

Kahnert K, Kauffmann-Guerrero D, Huber RM.

Clin Lung Cancer. 2016 Sep;17(5):325-333. doi: 10.1016/j.cllc.2016.05.014. Epub 2016 Jun 8. Review.

PMID:
27397481
43.

Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.

Tufman A, Huber RM, Völk S, Aigner F, Edelmann M, Gamarra F, Kiefl R, Kahnert K, Tian F, Boulesteix AL, Endres S, Kobold S.

BMC Cancer. 2016 Jul 7;16:409. doi: 10.1186/s12885-016-2471-2.

44.

Interactions among Lung Cancer Cells, Fibroblasts, and Macrophages in 3D Co-Cultures and the Impact on MMP-1 and VEGF Expression.

Liu XQ, Kiefl R, Roskopf C, Tian F, Huber RM.

PLoS One. 2016 May 27;11(5):e0156268. doi: 10.1371/journal.pone.0156268. eCollection 2016.

45.

Thoracic lymph node delineation at dose-reduced (1 mSv) dose-modulated contrast enhanced MDCT: a retrospective pilot study.

Paolini M, Wirth K, Tufman A, Reiser M, Huber RM, Mueller-Lisse UG.

Radiol Med. 2016 Aug;121(8):644-51. doi: 10.1007/s11547-016-0645-2. Epub 2016 May 6.

PMID:
27154525
46.

[Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, Griesinger F, Dietel M, Grohé C.

Pathologe. 2016 Mar;37(2):187-91. doi: 10.1007/s00292-016-0152-1. German. No abstract available.

PMID:
26984297
47.

[ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)].

von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, Griesinger F, Dietel M, Grohé Ch.

Pneumologie. 2016 Apr;70(4):277-81. doi: 10.1055/s-0042-102626. Epub 2016 Mar 16. German.

PMID:
26984109
48.

Tracheobronchial stents in mucopolysaccharidosis.

Karl R, Carola S, Regina E, Thomas N, Huber RM.

Int J Pediatr Otorhinolaryngol. 2016 Apr;83:187-92. doi: 10.1016/j.ijporl.2016.02.015. Epub 2016 Feb 22.

PMID:
26968075
49.

GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.

Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, De Almeida C, Edlich B, Fietkau R.

Strahlenther Onkol. 2016 Apr;192(4):216-22. doi: 10.1007/s00066-016-0941-8. Epub 2016 Jan 25.

PMID:
26809652
50.

Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens.

Schwarzkopf L, Wacker M, Holle R, Leidl R, Günster C, Adler JB, Huber RM.

Lung Cancer. 2015 Nov;90(2):274-80. doi: 10.1016/j.lungcan.2015.09.005. Epub 2015 Sep 10.

PMID:
26384433

Supplemental Content

Loading ...
Support Center